The responsible genes, hydroxyprostaglandin dehydrogenase (HPGD) and solute carrier organic anion transporter family member 2A1 (SLCO2A1), have been identified, leading to an understanding of the etiology and the development of treatment for skin and bone hypertrophy (37, 38). The gene discussed is SLCO2A1; the disease is hyperostosis.